Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C4H7NO3.C2H3Cl3O2 |
| Molecular Weight | 282.506 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(O)C(Cl)(Cl)Cl.CC(=O)NCC(O)=O
InChI
InChIKey=SULCNWZLMZPENK-UHFFFAOYSA-N
InChI=1S/C4H7NO3.C2H3Cl3O2/c1-3(6)5-2-4(7)8;3-2(4,5)1(6)7/h2H2,1H3,(H,5,6)(H,7,8);1,6-7H
| Molecular Formula | C2H3Cl3O2 |
| Molecular Weight | 165.403 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C4H7NO3 |
| Molecular Weight | 117.1033 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/ppa/chloral-hydrate.htmlCurator's Comment: description was created based on several sources, including
http://www.rxlist.com/noctec-drug/clinical-pharmacology.htm |
https://www.ncbi.nlm.nih.gov/pubmed/7834208
Sources: https://www.drugs.com/ppa/chloral-hydrate.html
Curator's Comment: description was created based on several sources, including
http://www.rxlist.com/noctec-drug/clinical-pharmacology.htm |
https://www.ncbi.nlm.nih.gov/pubmed/7834208
Chloral hydrate was discovered in 1832, and was used as a sedative in late 19th century. Chloral hydrate has not been approved by the FDA or the EMA, and is on the list of unapproved drugs that are prescribed for postoperative pain control, sedation and to prevent alcohol withdrawal and reduce anxiety associated with withdrawal of opiates or barbiturates. Mechanism of action of chloral hydrate is not known. It is generally believed that the central depressant effects are due to the principal pharmacologically active metabolite trichloroethanol, which has a plasma half- life of 8 to 10 hours, and acts by potentiating GABA-activated Cl currents.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7834208 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Unknown Approved UseAdjunct to opiates and analgesics for postoperative pain control |
|||
| Primary | Unknown Approved UseShort-term sedative and hypnotic (<2 weeks) |
|||
| Primary | Unknown Approved UseSedative/hypnotic for diagnostic procedures; sedative prior to EEG evaluations |
|||
| Preventing | Unknown Approved UseMonotherapy or concomitant with paraldehyde for prevention of alcohol withdrawal symptoms and/or to suppress syndrome once it develops |
|||
| Palliative | Unknown Approved UseReduction of anxiety associated with withdrawal of opiates or barbiturates |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Efficacy of the Sequential Administration of Melatonin, Hydroxyzine, and Chloral Hydrate for Recording Sleep EEGs in Children. | 2017-01 |
|
| The safety and efficacy of chloral hydrate sedation for pediatric ophthalmic procedures: a retrospective review. | 2013-11-18 |
|
| Acute drug administration in epilepsy: a review. | 2011-10 |
|
| Trichloroethanol potentiation of gamma-aminobutyric acid-activated chloride current in mouse hippocampal neurones. | 1994-10 |
|
| The efficacy of triazolam and chloral hydrate in geriatric insomniacs. | 1980 |
|
| Use of subjective responses to evaluate efficacy of mild analgesic-sedative combinations. | 1974-02 |
|
| Treatment of alcohol withdrawal syndromes. | 1971-03-05 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/ppa/chloral-hydrate.html
Sedation, anxiety: Oral: 250 mg 3 times daily. Hypnotic: Oral: 500-1000 mg 15-30 minutes before bedtime or 30 minutes prior to procedure, not to exceed 2000 mg per 24 hours.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:59:46 GMT 2025
by
admin
on
Mon Mar 31 17:59:46 GMT 2025
|
| Record UNII |
6WZ3595RLZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
N05CC03
Created by
admin on Mon Mar 31 17:59:46 GMT 2025 , Edited by admin on Mon Mar 31 17:59:46 GMT 2025
|
||
|
WHO-VATC |
QN05CC03
Created by
admin on Mon Mar 31 17:59:46 GMT 2025 , Edited by admin on Mon Mar 31 17:59:46 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL3707308
Created by
admin on Mon Mar 31 17:59:46 GMT 2025 , Edited by admin on Mon Mar 31 17:59:46 GMT 2025
|
PRIMARY | |||
|
4316
Created by
admin on Mon Mar 31 17:59:46 GMT 2025 , Edited by admin on Mon Mar 31 17:59:46 GMT 2025
|
PRIMARY | |||
|
DTXSID00169803
Created by
admin on Mon Mar 31 17:59:46 GMT 2025 , Edited by admin on Mon Mar 31 17:59:46 GMT 2025
|
PRIMARY | |||
|
Acetylglycinamide chloral hydrate
Created by
admin on Mon Mar 31 17:59:46 GMT 2025 , Edited by admin on Mon Mar 31 17:59:46 GMT 2025
|
PRIMARY | |||
|
6WZ3595RLZ
Created by
admin on Mon Mar 31 17:59:46 GMT 2025 , Edited by admin on Mon Mar 31 17:59:46 GMT 2025
|
PRIMARY | |||
|
71587019
Created by
admin on Mon Mar 31 17:59:46 GMT 2025 , Edited by admin on Mon Mar 31 17:59:46 GMT 2025
|
PRIMARY | |||
|
17427-14-4
Created by
admin on Mon Mar 31 17:59:46 GMT 2025 , Edited by admin on Mon Mar 31 17:59:46 GMT 2025
|
PRIMARY | |||
|
DB13402
Created by
admin on Mon Mar 31 17:59:46 GMT 2025 , Edited by admin on Mon Mar 31 17:59:46 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |